Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Up to $10.00

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) gapped up before the market opened on Thursday . The stock had previously closed at $10.00, but opened at $11.00. Amicus Therapeutics shares last traded at $10.50, with a volume of 225,473 shares traded.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on FOLD shares. Guggenheim upgraded shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Tuesday, May 14th. UBS Group lowered their price target on shares of Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Bank of America lowered their price target on shares of Amicus Therapeutics from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, May 10th. Finally, Wells Fargo & Company started coverage on shares of Amicus Therapeutics in a research report on Thursday, May 30th. They set an “overweight” rating and a $18.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Amicus Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $17.57.

Amicus Therapeutics Stock Up 10.7 %

The company has a current ratio of 3.03, a quick ratio of 2.61 and a debt-to-equity ratio of 2.97. The company has a market capitalization of $3.28 billion, a price-to-earnings ratio of -22.47 and a beta of 0.71. The firm’s fifty day simple moving average is $10.14 and its two-hundred day simple moving average is $11.08.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.04. Amicus Therapeutics had a negative net margin of 34.73% and a negative return on equity of 77.08%. The firm had revenue of $110.40 million for the quarter, compared to analyst estimates of $111.19 million. During the same period in the prior year, the business posted ($0.18) EPS. The business’s revenue for the quarter was up 27.9% compared to the same quarter last year. Sell-side analysts anticipate that Amicus Therapeutics, Inc. will post -0.12 EPS for the current year.

Insider Transactions at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $10.34, for a total value of $77,550.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $9,168,002.36. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $10.34, for a total value of $77,550.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $9,168,002.36. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Bradley L. Campbell sold 6,100 shares of the company’s stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $10.00, for a total transaction of $61,000.00. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $8,866,540. The disclosure for this sale can be found here. Company insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On Amicus Therapeutics

Large investors have recently added to or reduced their stakes in the business. Van ECK Associates Corp increased its position in shares of Amicus Therapeutics by 23.1% in the 4th quarter. Van ECK Associates Corp now owns 4,657 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 873 shares during the last quarter. Headlands Technologies LLC purchased a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at approximately $89,000. Calton & Associates Inc. purchased a new stake in shares of Amicus Therapeutics in the 4th quarter valued at approximately $142,000. Sage Capital Advisors llc purchased a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at approximately $103,000. Finally, Old Well Partners LLC purchased a new stake in shares of Amicus Therapeutics in the 4th quarter valued at approximately $180,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.